Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Fixed-Dose Combinations of Drugs versus Single-Drug Formulations for Treating Pulmonary Tuberculosis

About this resource:

Systematic review

Source: The Cochrane Collaborative

Last Reviewed: May 2016

Workgroups: Global Health Workgroup, Immunization and Infectious Diseases Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that fixed-dose combinations (FDCs) of anti-tuberculosis medicines may have similar effects as single‐drug formulations for treating people with newly diagnosed pulmonary tuberculosis. The treatment for pulmonary tuberculosis in new patients includes 4 medicines taken by mouth for 6 months, sometimes as FDCs that are combined in 1 tablet and sometimes taken separately as single-drug formulations. Researchers found little to no difference in outcomes for people taking FDCs compared with those taking single-drug formulations.

Read more about this resource

Objectives related to this resource (1)

Reduce tuberculosis cases — IID‑17
Little or no detectable change

Suggested Citation

1.

Gallardo, C.R., Rigau Comas, D., Valderrama Rodríguez, A., Roqué i Figuls, M., Parker, L.A., Caylà, J. & Bonfill Cosp, X. Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews, 2016 (5). DOI: 10.1002/14651858.CD009913.pub2